Compare Cassava Sciences Inc (FLNA) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs KLA Corp. — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while KLA Corp. trades at $201.2 (market cap $256.86B). The key difference: KLA Corp. is far larger — about 6519.3× Cassava Sciences Inc's market cap, and KLA Corp. pays a 0.47% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and KLA Corp. for 60 Days on average.
| FLNA | KLAC | |
|---|---|---|
Market Cap | $39.40M | $256.86B |
Volume | 759,018 | 7,016,455 |
Sector | Health | Technology |
52-Week High | $4.64 | $301.71 |
52-Week Low | $0.68 | $98.28 |
Typical Hold Time | 37 Days | 60 Days |
Enterprise Value | -$43.28M | $258.11B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
KLA Corporation (KLAC) trades at $196.83, down 0.32% on the day, with strong technical momentum indicated by bullish moving averages. The company shows robust fundamentals with Q2 2026 EPS beating expectations at $1.05 versus $1.00 estimate, and maintains impressive profitability metrics including 35.57% net income margin and 87.5% ROE. Recent news highlights AI-driven demand boosting KLA's $12.57 billion backlog and positioning the company for continued growth in semiconductor equipment markets.
KLA presents a compelling investment case with analyst consensus price target of $223.88 representing 14% upside potential. The stock benefits from strong AI infrastructure spending and dominant market position in semiconductor inspection equipment. Key risks include competitive pressures from Applied Materials and ASML, valuation multiples above industry averages, and potential margin compression from increased R&D spending. Institutional ownership remains strong with recent acquisitions by Envestnet Portfolio Solutions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
